|Day Low/High||28.63 / 28.68|
|52 Wk Low/High||17.50 / 30.10|
A Novel Sustained-Release Candidate for Treatment of Schizophrenia
Agreement Relates to Intellectual Property for RBP-7000, Indivior's Investigational Once-Monthly Injectable Risperidone Product for Schizophrenia
The U.S. opioid crisis rages on. TheStreet takes a look at several drugs being used to help treat people.
The FTSE 250 pharmaceutical company said the U.S. District Court in Delaware has found that claims of a proposed generic version of Indivior's opioid addiction treatment by Dr. Reddy's does not infringe patents.
FDA Sets a PDUFA target action date of November 30, 2017
Data Presented in Late-Breaking Research Oral Session at CPDD 79th Annual Scientific Meeting 2017
Société Générale, Deutsche Bank among biggest losers.
Indivior shares drop 16% in London on news of the lawsuit.
Semiconductor industry player ASML falls on reported snub from Intel.
U.S. futures point to markets opening in the red.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.